Lactobacillus crispatus

Lactobacillus crispatus is a homofermentative species and the dominant member of the healthy vaginal microbiota in many women, where it maintains a low-pH environment through lactic acid production and competitive exclusion of pathogens.

Supplied as a freeze-dried powder with viability between 50 and 300 billion CFU per gram at release. The species produces both D-lactic and L-lactic acid isomers, with hydrogen peroxide generation in many strains contributing to vaginal microbiome stability.

Off-white to pale beige free-flowing powder with a faintly fermented note. Particle size suitable for vaginal capsules, oral capsules, sachets, and topical microbiome products.

We supply food-grade Lactobacillus crispatus from manufacturers in China holding ISO 22000, FSSC 22000, Halal, Kosher, and other certifications relevant to probiotic strain production.

Common market grades include 50, 100, and 300 billion CFU per gram freeze-dried powders, vaginal capsule and pessary premixes, oral capsule grades for systemic urogenital support, and topical microbiome cosmetic-grade powders. Bulk and reduced-MOQ shipments with batch-level COA covering viable count, strain identity, moisture, heavy metals, and pathogen panel.

Lactobacillus crispatus was first described in 1953 and recognized as a defining member of the Community State Type I vaginal microbiome through landmark sequencing work in the 2000s. Reference strains include ATCC 33820 and several proprietary commercial strains used in vaginal health products.

Industrial production uses MRS-based proprietary media under anaerobic conditions optimized for vaginal-niche isolates, with biomass harvest, cryoprotectant blending, and lyophilization. Vaginal capsule and pessary premixes are produced under strict bioburden control to support the regulatory requirements of intimate care products.

Regulatory status includes Qualified Presumption of Safety listing in the European Union, GRAS notifications with FDA for specific oral-use strains, and inclusion in approved medical device and pharmaceutical formulations for vaginal application in several markets.

Clinical evidence supports use in recurrent bacterial vaginosis prevention, urinary tract infection adjunct support, and maintenance of healthy vaginal microbiome composition through both vaginal and oral delivery routes.

• Vaginal probiotic capsules, pessaries, and suppositories
• Oral capsules for urogenital microbiome support
• Women's health and bacterial vaginosis adjunct formulations
• Pregnancy and postpartum support supplements
• Topical microbiome cosmetic and intimate care products
• Urinary tract health supplements
• Multi-strain women's health probiotic stacks
• Synbiotic formulations with vaginal-targeted prebiotics
• Postbiotic and tyndallized cell topical applications